颅内脑膜瘤患者长期随访期间的医疗资源利用与费用
该多中心横断面研究纳入190例WHO I或II级脑膜瘤术后平均9.2年(SD 4.0)的成人患者,评估其过去12个月医疗资源利用与费用。结果显示全科医生(80.5%)、物理治疗师(37.9%)和神经科医生(25.4%)就诊最多,中位年医疗费用为871欧元(IQR 262-1933欧元),药物占总费用45.8%(其中抗癫痫药物占21.6%)。较低健康相关生活质量是医疗资源利用和费用较高的显著决定因素。
要点
- 脑膜瘤术后平均9.2年患者中位年医疗费用为871欧元(IQR 262-1933欧元)。
- 药物占总费用45.8%,其中抗癫痫药物占21.6%,为最大支出项目。
- 较低健康相关生活质量是医疗资源利用和费用较高的显著决定因素。
核心结论
- 脑膜瘤患者中药物费用占总医疗费用最大份额,尤其是抗癫痫药物。
- 较低健康相关生活质量是医疗资源利用和费用的决定因素。
- 作者认为针对改善患者健康相关生活质量和需求的个体化方法可能有助于减轻疾病负担和功能恢复。
研究设计与样本
- 多中心横断面研究,纳入190例成人脑膜瘤患者,均为WHO I或II级,干预后≥5年,平均随访9.2年(SD 4.0)。
- 患者完成三种验证过的患者报告结局测量工具(SF-36、EORTC QLQ-BN20和HADS)及一份研究特异性问卷,评估过去12个月医疗资源利用。
- 采用荷兰医疗经济学评价手册计算过去12个月医疗费用,并通过回归分析确定医疗资源利用和费用的决定因素。
主要发现
- 全科医生就诊率80.5%,物理治疗师37.9%,神经科医生25.4%,为患者最常就诊的医疗服务提供者。
- 中位年医疗费用为871欧元(IQR 262-1933欧元)。
- 费用主要构成:药物占总费用45.8%(其中抗癫痫药物占21.6%),专科护理占17.7%,物理治疗占15.5%。
- 较低健康相关生活质量是医疗资源利用和费用较高的显著决定因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Few studies have reported on healthcare utilization and costs for intracranial meningioma patients, while the tumor and its treatment profoundly affect patients' functioning and well-being. Here we evaluated healthcare utilization and costs, including their determinants. METHODS: A multicenter cross-sectional study of adult meningioma patients ≥ 5 years after intervention. Patients completed three validated patient-reported outcome measures (PROMs) assessing patients 'functioning and wellbeing (SF-36, EORTC QLQ-BN20, and HADS) and a study-specific questionnaire assessing healthcare utilization over the previous twelve months. Healthcare costs of the twelve months prior were calculated using reported healthcare utilization ≥ 5 years after intervention by the Dutch Manual for Economic Evaluation in Healthcare. Determinants for healthcare utilization and costs were determined with regression analyses. RESULTS: We included 190 patients with WHO grade I or II meningioma after a mean follow-up since intervention of 9.2 years (SD 4.0). The general practitioner (80.5%), physiotherapist (37.9%), and neurologist (25.4%) were visited most often by patients. Median annual healthcare costs were €871 (IQR €262-€1933). Main contributors to these costs were medication (45.8% of total costs, of which anti-seizure medication was utilized most [21.6%]), specialist care (17.7%), and physiotherapy (15.5%). Lower HRQoL was a significant determinant for higher healthcare utilization and costs. CONCLUSION: In patients with meningioma, medication costs constituted the largest expenditure of total healthcare costs, in particular anti-seizure medication. Particularly a lower HRQoL was a determinant for healthcare utilization and costs. A patient-specific approach aimed at improving patients' HRQoL and needs could be beneficial in reducing disease burden and functional recovery.
引用
- Huynh KA, Coopmans EC, Zamanipoor Najafabadi AH, et al. Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up. J Neurooncol. 2023. PMID: 36626042. doi:10.1007/s11060-022-04223-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。